Midazolam Aurum Pharmaceuticals (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor, increasing chloride ion flow into neurons. This hyper‑polarizes the cells, reducing neuronal firing and producing sedation, anxiolysis, anticonvulsant effects, and muscle relaxation.

The dose of Midazolam is individualized and set by the prescribing clinician based on the patient’s age, weight, clinical condition, and intended use. Dosing regimens are established in hospital protocols and should not be altered without medical guidance.

Midazolam is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used only if the potential benefit justifies any possible risk to the fetus, and caution is advised during breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with other benzodiazepines, Midazolam has a rapid onset and short duration, making it suitable for procedural sedation. Unlike propofol, it provides anxiolysis and amnesia but may cause more pronounced respiratory depression, so monitoring requirements differ.

Midazolam injectable solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Use aseptic technique when drawing the solution, and discard any vial that shows particulate matter or discoloration.

Midazolam is administered intravenously, either as a rapid bolus injection for immediate effect or as a controlled infusion for continuous sedation. Administration is performed by qualified healthcare professionals in settings equipped for airway management and vital‑sign monitoring.

The most serious risks include severe respiratory depression, profound hypotension, paradoxical agitation or aggression, and rare anaphylactic reactions. Prompt recognition and supportive measures, such as airway management and cardiovascular support, are essential.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals where sedation could compromise airway protection. Caution is also advised in the elderly and in patients with significant hepatic impairment.